Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

被引：7

作者：

Touzeau, Cyrille ^{[1
]}

Perrot, Aurore ^{[2
]}

Hulin, Cyrille ^{[3
]}

Manier, Salomon ^{[4
]}

Macro, Margaret ^{[5
]}

Chretien, Marie-Lorraine ^{[6
]}

Karlin, Lionel ^{[7
]}

Decaux, Olivier ^{[8
]}

Jacquet, Caroline ^{[9
]}

Tiab, Mourad ^{[10
]}

Leleu, Xavier ^{[11
]}

Corre, Jill ^{[12
]}

Jobert, Alexandra ^{[13
]}

Planche, Lucie ^{[14
]}

Avet-Loiseau, Herve ^{[15
]}

Moreau, Philippe ^{[16
]}

机构：

[1] Ctr Hosp Univ Nantes, Nantes, France

[2] CRCT, Toulouse, France

[3] Ctr Hosp Univ Bordeaux, Pessac, France

[4] Ctr Hosp Univ Hop Huriez, Lille, France

[5] Hop Cote Nacre, Caen, France

[6] CHU Dijon, Dijon, France

[7] CH Lyon Sud, Pierre Benite, France

[8] Ctr Hosp Univ Rennes Hop Pontchaillou, Rennes, France

[9] CHU Nancy, Vandoeuvre Les Nancy, France

[10] Ctr Hosp Dept, La Roche Sur Yon 9, France

[11] Serv Dhematol & Therapie Cellulaire, Poitiers, France

[12] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[13] Ctr Hosp Univ, Nantes, France

[14] CHU Nantes, Nantes, France

[15] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[16] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174044

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)
Derman, Benjamin A.
Cooperrider, Jennifer H.
Rosenblatt, Jacalyn
Avigan, David
Rampurwala, Murtuza M.
Major, Ajay
Karrison, Theodore
Jiang, Ken
Kubicki, Tadeusz
Jakubowiak, Andrzej J.
BLOOD, 2023, 142
[22] Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
Mina, Roberto
Bonello, Francesca
Petrucci, Maria Teresa
Liberati, Anna Marina
Conticello, Concetta
Ballanti, Stelvio
Musto, Pellegrino
Olivieri, Attilio
Benevolo, Giulia
Capra, Andrea
Gilestro, Milena
Galieni, Piero
Cavo, Michele
Siniscalchi, Agostina
Palumbo, Antonio
Montefusco, Vittorio
Gaidano, Gianluca
Omede, Paola
Boccadoro, Mario
Bringhen, Sara
HAEMATOLOGICA, 2021, 106 (04) : 1079 - 1085
[23] Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Usmani, Saad Z.
Facon, Thierry
Hungria, Vania
Bahlis, Nizar J.
Venner, Christopher P.
Braunstein, Marc
Pour, Ludek
Marti, Josep
Basu, Supratik
Cohen, Yael C.
Matsumoto, Morio
Suzuki, Kenshi
Hulin, Cyrille
Grosicki, Sebastian
Legiec, Wojciech
Beksac, Meral
Maiolino, Angelo
Liu, Weiping
Wang, Jianping
Krevvata, Maria
Lopez-Masi, Lorena
Carey, Jodi
Rowe, Melissa
Carson, Robin
Zweegman, Sonja
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S288 - S289
[24] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Hiroyuki Takamatsu
Shinsuke Iida
Hirohiko Shibayama
Kazuhiro Shibayama
Hiroshi Yamazaki
Kenshi Suzuki
International Journal of Hematology, 2020, 111 : 692 - 701
[25] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Takamatsu, Hiroyuki
Iida, Shinsuke
Shibayama, Hirohiko
Shibayama, Kazuhiro
Yamazaki, Hiroshi
Suzuki, Kenshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 692 - 701
[26] Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone plus /- daratumumab induction regimen
Meseha, Mina
Abusamra, Murad
Farooki, Azeez
Derkach, Andriy
Maclachlan, Kylee
Hultcrantz, Malin
Hassoun, Hani
Shah, Urvi
Lu, Sydney
Mailankody, Sham
Patel, Dhwani
Lahoud, Oscar
Shah, Gunjan
Scordo, Michael
Chung, David
Landau, Heather
Lesokhin, Alexander
Korde, Neha
Giralt, Sergio
Usmani, Saad
Tan, Carlyn
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S139 - S140
[27] A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
Patel, Roshani
Bhaskarla, Amrit
Gordon, Max J.
Emanuel, Michael
Colon, Dana I. Delgado
Wang, Hao-Wei
Yuan, Constance M.
Lindenberg, Liza
Mena, Esther
Turkbey, Baris
Micheletti, Nick
Yee, Laura M.
Patel, Nisha
Maric, Irina
Braylan, Raul C.
Calvo, Katherine R.
Staudt, Louis M.
Young, Ryan M.
Roschewski, Mark
Kazandjian, Dickran
Hill, Elizabeth
BLOOD, 2024, 144 : 7059 - 7060
[28] Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Kapoor, Prashant
Gertz, Morie A.
Laplant, Betsy
Malave, Gabriella C.
Wolfe, Eric
Muchtar, Eli
Siddiqui, Mustaqeem A.
Gonsalves, Wilson I.
Emanuel, Angie R.
Kourelis, Taxiarchis
Warsame, Rahma
Dingli, David
Buadi, Francis K.
Hayman, Suzanne R.
Leung, Nelson
Hwa, Yi L.
Hobbs, Miriam A.
Fonder, Amie
Dispenzieri, Angela
Lacy, Martha Q.
Rajkumar, S. Vincent
Kumar, Shaji K.
BLOOD, 2019, 134
[29] Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03
Perrot, Aurore
Roussel, Murielle
Lauwers-Cances, Valerie
Hulin, Cyrille
Leleu, Xavier
Touzeau, Cyrille
Facon, Thierry
Mariette, Clara
Schiano, Jean-Marc
Gay, Julie
Montes, Lydia
Ranta, Dana
Huguet, Amandine
Wuilleme, Soraya
Dejoie, Thomas
Devlamynck, Laure
Corre, Jill
Avet-Loiseau, Herve
Moreau, Philippe
Attal, Michel
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 891 - 899
[30] Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk
Broijl, Annemiek
Sonneveld, Pieter
HAEMATOLOGICA, 2019, 104 (11) : 2265 - 2273

← 1 2 3 4 5 →